AC Immune
Clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
* | $50.1m | Post IPO Equity | |
| Total Funding | 000k | ||
| CHF | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (66 %) | 1340 % | (86 %) | - | - | 276 % | 85 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (718 %) | 42 % | (384 %) | - | (1799 %) | (340 %) | (172 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (737 %) | 41 % | (401 %) | - | (1798 %) | (366 %) | (186 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 641 % | 45 % | 386 % | - | 1533 % | 369 % | 229 % |
Source: Company filings or news article
Related Content
AC Immune is a biopharmaceutical company specializing in the development of innovative therapies and diagnostics for neurodegenerative diseases, such as Alzheimer's and Parkinson's. The company operates in the biotechnology sector and primarily serves patients, healthcare providers, and pharmaceutical companies. AC Immune's business model revolves around leveraging its proprietary technology platforms to create a broad pipeline of products aimed at treating and diagnosing neurodegenerative conditions. The company generates revenue through partnerships, licensing agreements, and milestone payments from larger pharmaceutical firms. AC Immune's goal is to become a global leader in precision medicine for neurodegenerative diseases, addressing one of the most significant challenges facing society today.
Keywords: biopharmaceutical, neurodegenerative, Alzheimer's, Parkinson's, diagnostics, therapies, biotechnology, proprietary technology, precision medicine, healthcare.